MAPKAP kinase 2 inhibitors (Pfizer)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameMAPKAP kinase 2 inhibitors (Pfizer)
Drug Alias NameMAPKAP kinase 2 inhibitors (Wyeth)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMAP kinase-activated protein kinase 2 inhibitors
TargetsMAP kinase-activated protein kinase 2
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWyeth Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth LlcPfizer Inc
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A